3SBio Inc.

In the top alliance by deal value, Pfizer entered into an exclusive global, ex-China, licensing agreement with 3SBio for the development, manufacturing, and commercialization of SSGJ-707, a bispecific

Bristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech

Pfizer has thrust into the global race for a best-in-class bispecific antibody that inhibits both programmed cell death protein 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF) as it

While President Trump’s efforts to downsize the US Food and Drug Administration and plans to impose tariffs are currently spooking biopharma investors, some companies were able to defy the gloomy sent